Last reviewed · How we verify
Prompt aflibercept
Prompt aflibercept is a VEGF inhibitor / Antiangiogenic agent Small molecule drug developed by Jaeb Center for Health Research. It is currently in Phase 3 development for Diabetic macular edema (DME), Retinal vein occlusion (RVO), Wet age-related macular degeneration (AMD). Also known as: intravitreal anti-vascular endothelial growth factor, Eylea, intravitreal anti-VEGF.
Aflibercept is a soluble decoy receptor that binds and neutralizes vascular endothelial growth factor (VEGF) and placental growth factor (PlGF) to inhibit angiogenesis.
Aflibercept is a soluble decoy receptor that binds and neutralizes vascular endothelial growth factor (VEGF) and placental growth factor (PlGF) to inhibit angiogenesis. Used for Diabetic macular edema (DME), Retinal vein occlusion (RVO), Wet age-related macular degeneration (AMD).
At a glance
| Generic name | Prompt aflibercept |
|---|---|
| Also known as | intravitreal anti-vascular endothelial growth factor, Eylea, intravitreal anti-VEGF |
| Sponsor | Jaeb Center for Health Research |
| Drug class | VEGF inhibitor / Antiangiogenic agent |
| Target | VEGF (vascular endothelial growth factor), PlGF (placental growth factor) |
| Modality | Small molecule |
| Therapeutic area | Oncology, Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
Aflibercept functions as a fusion protein combining VEGF-binding domains from VEGF receptors 1 and 2 with the Fc portion of human immunoglobulin G. By sequestering circulating VEGF and PlGF, it prevents these growth factors from activating their cognate receptors on endothelial cells, thereby suppressing new blood vessel formation that supports tumor growth and pathological neovascularization in retinal diseases.
Approved indications
- Diabetic macular edema (DME)
- Retinal vein occlusion (RVO)
- Wet age-related macular degeneration (AMD)
- Metastatic colorectal cancer (in combination with chemotherapy)
Common side effects
- Conjunctival hemorrhage
- Eye pain
- Floaters
- Intraocular pressure elevation
- Arterial thromboembolic events
Key clinical trials
- Anti-VEGF Treatment for Prevention of PDR/DME (PHASE3)
- Anti-VEGF vs. Prompt Vitrectomy for VH From PDR (PHASE2, PHASE3)
- Treatment for CI-DME in Eyes With Very Good VA Study (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Prompt aflibercept CI brief — competitive landscape report
- Prompt aflibercept updates RSS · CI watch RSS
- Jaeb Center for Health Research portfolio CI
Frequently asked questions about Prompt aflibercept
What is Prompt aflibercept?
How does Prompt aflibercept work?
What is Prompt aflibercept used for?
Who makes Prompt aflibercept?
Is Prompt aflibercept also known as anything else?
What drug class is Prompt aflibercept in?
What development phase is Prompt aflibercept in?
What are the side effects of Prompt aflibercept?
What does Prompt aflibercept target?
Related
- Drug class: All VEGF inhibitor / Antiangiogenic agent drugs
- Target: All drugs targeting VEGF (vascular endothelial growth factor), PlGF (placental growth factor)
- Manufacturer: Jaeb Center for Health Research — full pipeline
- Therapeutic area: All drugs in Oncology, Ophthalmology
- Indication: Drugs for Diabetic macular edema (DME)
- Indication: Drugs for Retinal vein occlusion (RVO)
- Indication: Drugs for Wet age-related macular degeneration (AMD)
- Also known as: intravitreal anti-vascular endothelial growth factor, Eylea, intravitreal anti-VEGF
- Compare: Prompt aflibercept vs similar drugs
- Pricing: Prompt aflibercept cost, discount & access